StockMacro
Company, fund or insider

Help

Menu

Sionna Therapeutics

$2.83 -93% in 6 monthsMarket cap $127.8M

SION on XNAS, Health Care, Sionna Therapeutics, Inc., job postings

Measures activity, not value. Not investment advice.

Shares down 93% in a year while insiders sold $21.8M and bought nothing.

  • WatchCash $249.8M, more than the $134.3M market value
  • BadShort interest 9.3% of shares, rising 15% over two weeks

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.

Industry
Pharmaceutical preparations (Health Care)
Employees
59
Website
sionnatx.com
Listed
Nasdaq, US
Last results
10 Nov 2026
Next results
expected around 1 Mar 2027 (an estimate: a year ago it reported on 2 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $32.4M.
Quarter to 31 Mar 2024: revenue –, net income -$11.8MQuarter to 30 Jun 2024: revenue –, net income -$8.6MQuarter to 30 Sep 2024: revenue –, net income -$25.4MQuarter to 31 Dec 2024: revenue –, net income -$15.8MQuarter to 31 Mar 2025: revenue –, net income -$16.5MQuarter to 30 Jun 2025: revenue –, net income -$18.1MQuarter to 30 Sep 2025: revenue –, net income -$20.3MQuarter to 31 Dec 2025: revenue –, net income -$20.4MQuarter to 31 Mar 2026: revenue –, net income -$26.8MQuarter to 30 Jun 2026: revenue –, net income -$29.9MQuarter to 30 Sep 2026: revenue –, net income -$32.4M
31 Mar 2024RevenueNet incomeNet losstallest bar $32.4M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026–-$32.4M
30 Jun 2026–-$29.9M
31 Mar 2026–-$26.8M
31 Dec 2025–-$20.4M
30 Sep 2025–-$20.3M
30 Jun 2025–-$18.1M
31 Mar 2025–-$16.5M
31 Dec 2024–-$15.8M
30 Sep 2024–-$25.4M
30 Jun 2024–-$8.6M
31 Mar 2024–-$11.8M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$109.5M -$70.7M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$2.43 -$4.67
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -39.0% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $249.8M $325.0M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$249.8M (net cash) -$325.0M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $5.32
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 0.53 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Sionna TherapeuticsSION (this company) $127.8Mloss–––
MacroGenicsMGNX $125.3Mloss1.1+23%-45.4%
Zentalis PharmaceuticalsZNTL $133.6Mloss–––
ALX OncologyALXO $137.0Mloss–––
BridgeBio Oncology TherapeuticsBBOT $145.3Mloss–––
OnKure TherapeuticsOKUR $111.2Mloss–––

Insider buy/sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$21.8M

bought $0, sold $21.8M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-9.5%

133 13F filers vs 147

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

over 100%

45.5M shares held by 13F filers (30 Sep 2026) of 45.2M outstanding (30 Oct 2026); above 100%: the share count is probably stale

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

9.3%

4.2M shares sold short (30 Oct 2026) of 45.2M outstanding (30 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

4.1

4.2M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+15%

3.7M shares sold short in the report before, 4.2M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

50%

50% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 56%

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

6

6 articles in the last 7 days; its usual week has 2 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

3.0×

6 articles in the last 7 days; its usual week has 2.

Price $2.83 on 20 Nov 2026, -93% over 12 months (12-month range $2.83 to $51.04)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders sold a net $83.9M in the last 12 months (the 12 months before: -$4.5M).
Capital spending per quarter. Capital spending $0 in the latest quarter, -100% on a year earlier.
Institutional holders (13F filers). 133 13F filers reported holding it in the latest 13F quarter, +75% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, revenue per quarter, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
14 Sep 20268-K and other filingsDirector or officer change
14 Sep 20268-K and other filingsRestructuring costs announced
14 Sep 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
11 Feb 2025Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 31.2M)
3 Feb 20258-K and other filingsRegistered new securities for sale (S-1)
17 Jan 20258-K and other filingsRegistered new securities for sale (S-1)
Insider net buying (open market)
Month from 1 Feb 2025: $51.5M published
Month from 1 Jul 2025: $950K published
Month from 1 Aug 2025: -$2.9M published
Month from 1 Sep 2025: -$477K published
Month from 1 Oct 2025: -$42.0M published
Month from 1 Nov 2025: -$11.5M published
Month from 1 Dec 2025: -$2.0M published
Month from 1 Jan 2026: -$10.0M published
Month from 1 Feb 2026: -$1.4M published
Month from 1 Mar 2026: -$347K published
Month from 1 Apr 2026: -$25.4M published
Month from 1 May 2026: -$13.4M published
Month from 1 Jul 2026: -$9.6M published
Month from 1 Sep 2026: -$21.8M published
Capital spending per quarter
Quarter ended 31 Mar 2024: $0; public on 13 May 2025
Quarter ended 30 Jun 2024: $0; public on 12 Aug 2025
Quarter ended 30 Sep 2024: $0; public on 6 Nov 2025
Quarter ended 31 Dec 2024: $27K; public on 3 Mar 2026
Quarter ended 31 Mar 2025: $86K; public on 13 May 2025
Quarter ended 30 Sep 2025: $87K; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $204K, +656% on a year earlier; public on 3 Mar 2026
Quarter ended 31 Mar 2026: $0, -100% on a year earlier; public on 13 May 2026
Quarter ended 30 Sep 2026: $0, -100% on a year earlier; public on 11 Nov 2026
Institutional holders (13F filers)
31 Mar 2025 report: 47; public on 15 May 2025
30 Jun 2025 report: 63; public on 14 Aug 2025
30 Sep 2025 report: 76; public on 14 Nov 2025
31 Dec 2025 report: 99; public on 17 Feb 2026
31 Mar 2026 report: 120; public on 15 May 2026
30 Jun 2026 report: 147; public on 14 Aug 2026
30 Sep 2026 report: 133; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is capital expenditure, fiscal year at $377K (31 Dec 2025), 14× its normal quarter.
  • Insider net buying (open market): Insiders sold a net $83.9M in the last 12 months (the 12 months before: -$4.5M).
  • Capital spending per quarter: Capital spending $0 in the latest quarter, -100% on a year earlier.
  • Institutional holders (13F filers): 133 13F filers reported holding it in the latest 13F quarter, +75% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 49 insider trades

Last 90 days: 1 sale, $21.8M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
21 Sep 2026Ra Capital Management, L.P. and 5 othersDirector, 10% ownerSell3,448,811$6.33$21.8MForm 4
9 Jul 2026OrbiMed Capital GP VIII LLC and 1 otherDirectorSellplanned in advance (10b5-1)85,918$44.86$3.9MForm 4
7 Jul 2026Jennifer FitzpatrickChief Legal OfficerSellplanned in advance (10b5-1); after exercising options10,250$43.60$447KForm 4
2 Jul 2026Orbimed Advisors LLC and 1 otherDirectorSellplanned in advance (10b5-1)115,844$45.50$5.3MForm 4
29 May 2026Orbimed Advisors LLC and 1 otherDirectorSellplanned in advance (10b5-1)101$44.49$4KForm 4
11 May 2026Orbimed Advisors LLC and 1 otherDirectorSellplanned in advance (10b5-1)292,952$45.62$13.4MForm 4
21 Apr 2026Orbimed Advisors LLC and 1 otherDirectorSellplanned in advance (10b5-1)55,345$44.67$2.5MForm 4
16 Apr 2026Orbimed Advisors LLC and 1 otherDirectorSellplanned in advance (10b5-1)510,583$44.94$22.9MForm 4

133 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 42 opened a position, 53 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
TPG GP A, LLC6.5M14.4%$34.2MNo change
Ra Capital Management, L.P.6.5M14.3%$34.0M-3.4M-35%
Viking Global Investors LP3.2M7.06%$16.8MNo change
Atlas Venture Life Science Advisors, LLC3.0M6.62%$15.8MNo change
Goldman Sachs Group Inc2.7M6.01%$14.3M+2.3M+600%
BlackRock, Inc.2.7M5.91%$14.1M+1.2M+81%
Enavate Sciences GP, LLC2.5M5.48%$13.0MNo change
Orbimed Advisors LLC2.5M5.46%$13.0M-86K-3.4%
Jennison Associates LLC2.0M4.41%$10.5M+821K+70%
Millennium Management LLC1.5M3.23%$7.7M+1.2M+429%

Company events

All 4 company events

In 12 months: 1 restructuring, 1 director or officer change. Results releases and routine reports are left out.

FiledWhat happenedSource
14 Sep 2026Director or officer change; Restructuring costs announced8-K
3 Feb 2025Registered new securities for sale (S-1)S-1/A
17 Jan 2025Registered new securities for sale (S-1)S-1

The 5 newest of 131 articles that name the company.

Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 14 Sep 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  2. 14 Sep 2026Filings record

    Director or officer change

  3. 14 Sep 2026Filings record

    Restructuring costs announced

  4. 2 Jul 2025Insiders record

    COULTER JAMES G (ten percent owner) and 2 other(s) bought 60,000 shares of SION ($950,400) (dated 1 Jul 2025)

  5. 13 Feb 2025Insiders record

    TPG GP A, LLC (ten percent owner) and 2 other(s) bought 1,125,000 shares of SION ($20.2M) (dated 12 Feb 2025)

  6. 11 Feb 2025Insiders change

    had 3 insiders buy $31.2M of its shares on the open market within 30 days (3 filings).

    Who bought: Booth Bruce.

    See the evidence (3 source records)
    Independent buyers
    3
    Purchase filings (Form 4, code P)
    3
    Total bought
    $31.2M
    Window
    12 Jan 2025 to 11 Feb 2025

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  7. 11 Feb 2025Insiders record

    Thompson Peter A. (director) bought 550,000 shares of SION [same transaction as an earlier filing] (dated 10 Feb 2025)

  8. 11 Feb 2025Insiders record

    Atlas Venture Fund XI, L.P. (ten percent owner) and 5 other(s) bought 60,000 shares of SION [same transaction as an earlier filing] (dated 10 Feb 2025)

  9. 11 Feb 2025Insiders record

    OrbiMed Capital GP VIII LLC (director) and 1 other(s) bought 550,000 shares of SION ($9.9M) (dated 10 Feb 2025)

  10. 11 Feb 2025Insiders record

    RA CAPITAL MANAGEMENT, L.P. (director) and 5 other(s) bought 1,125,000 shares of SION ($20.2M) (dated 10 Feb 2025)

  11. 11 Feb 2025Insiders record

    Booth Bruce (director) bought 60,000 shares of SION ($1.1M) (dated 10 Feb 2025)

  12. 3 Feb 2025Filings record

    Registered new securities for sale (S-1)

  13. 17 Jan 2025Filings record

    Registered new securities for sale (S-1)

Not listed: 60 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0002036042
Ticker
SION
Domain
sionnatx.com
Hq location
MA|WALTHAM|02451 (1 unverified)
Name
Sionna Therapeutics, Inc.
  • SEC Form 13F institutional holdings63 data points31 Mar 2025 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)22 records17 Jan 2025 to 10 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)145 data points31 Dec 2023 to 30 Oct 2026
  • SEC Form 4 insider transactions49 records, 132 data points10 Feb 2025 to 21 Sep 2026
  • FINRA short interest (twice monthly)125 data points14 Feb 2025 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)900 data points7 Feb 2025 to 20 Nov 2026